CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: Implications for optimization of receptor structure for adoptive cell therapy

Clinical and Experimental Immunology

Volumn 175, Issue 2, 2014, Pages 258-267

  Bridgeman, J S ^a,b   Ladell, K ^b   Sheard, V E ^a   Miners, K ^b   Hawkins, R E ^a   Price, D A ^b   Gilham, D E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Gene therapy; T cells; Therapy immunotherapy

Indexed keywords

CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; HETERODIMER; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE RECEPTOR; POLYFUNCTIONAL GROUP; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL THERAPY; HUMAN; HUMAN CELL; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; INTRACELLULAR SIGNALING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSACTIVATION; WESTERN BLOTTING;

GENE THERAPY; T CELLS; THERAPY/IMMUNOTHERAPY;

ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTIGENS, NEOPLASM; CELL LINE; HEK293 CELLS; HUMANS; IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF; IMMUNOTHERAPY, ADOPTIVE; JURKAT CELLS; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION;

EID: 84891594672     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12216     Document Type: Article

References (31)

1. Cheadle EJ, Gilham DE, Hawkins RE. The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol 2008; 142:65-68.
2. Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother 2009; 32:207-218.
3. Cheadle EJ, Rothwell DG, Bridgeman JS, Sheard VE, Hawkins RE, Gilham DE. Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Ther 2011; 19:1114-1120.
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-733.
5. Morgan RA, Dudley ME, Wunderlich JR etal. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-129.
6. Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE. Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010; 10:77-90.
7. Grupp SA, Kalos M, Barrett D etal. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-1518.
8. Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 2004; 172:104-113.
9. Shirasu N, Shibaguci H, Kuroki M, Yamada H. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer Res 2010; 30:2731-2738.
10. Schroten C, Kraaij R, Veldhoven JL etal. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. J Immunol Methods 2010; 359:11-20.
11. Annenkov AE, Moyes SP, Eshhar Z, Mageed RA, Chernajovsky Y. Loss of original antigenic specificity in T cell hybridomas transduced with a chimeric receptor containing single-chain Fv of an anti-collagen antibody and Fc epsilonRI-signaling gamma subunit. J Immunol 1998; 161:6604-6613.
12. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 2010; 184:6938-6949.
13. Gilham DE, O'Neil A, Hughes C etal. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother 2002; 25:139-151.
14. Guest RD, Hawkins RE, Kirillova N etal. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005; 28:203-211.
15. Finer MH, Dull TJ, Qin L, Farson D, Roberts MR. Kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83:43-50.
16. Roederer M, Nozzi JL, Nason MC. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011; 79:167-174.
17. Chae WJ, Lee HK, Han JH etal. Qualitatively differential regulation of T cell activation and apoptosis by T cell receptor zeta chain ITAMs and their tyrosine residues. Int Immunol 2004; 16:1225-1236.
18. Alcover A, Alberini C, Acuto O etal. Interdependence of CD3-Ti and CD2 activation pathways in human T lymphocytes. EMBO J 1988; 7:1973-1977.
19. Sussman JJ, Bonifacino JS, Lippincott-Schwartz J etal. Failure to synthesize the T cell CD3-zeta chain: structure and function of a partial T cell receptor complex. Cell 1988; 52:85-95.
20. Bridgeman JS, Blaylock M, Hawkins RE, Gilham DE. Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis. Cytometry A 2010; 77:338-346.
21. Kersh EN, Kersh GJ, Allen PM. Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med 1999; 190:1627-1636.
22. Li YC, Chen BM, Wu PC etal. Cutting edge: mechanical forces acting on T cells immobilized via the TCR complex can trigger TCR signaling. J Immunol 2010; 184:5959-5963.
23. Mukherjee P, Kass I, Arkin IT, Zanni MT. Structural disorder of the CD3zeta transmembrane domain studied with 2D IR spectroscopy and molecular dynamics simulations. J Phys Chem B 2006; 110:24740-24749.
24. Mukherjee P, Kass I, Arkin IT, Zanni MT. Picosecond dynamics of a membrane protein revealed by 2D IR. Proc Natl Acad Sci USA 2006; 103:3528-3533.
25. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3:123-132.
26. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001; 98:2364-2371.
27. Heuser C, Hombach A, Losch C, Manista K, Abken H. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther 2003; 10:1408-1419.
28. Darcy PK, Haynes NM, Snook MB etal. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 2000; 164:3705-3712.
29. Combadiere B, Freedman M, Chen L, Shores EW, Love P, Lenardo MJ. Qualitative and quantitative contributions of the T cell receptor zeta chain to mature T cell apoptosis. J Exp Med 1996; 183:2109-2117.
30. Kong S, Sengupta S, Tyler B etal. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012; 18:5949-5960.
31. Wiest DL, Yuan L, Jefferson J etal. Regulation of T cell receptor expression in immature CD4+CD8+ thymocytes by p56lck tyrosine kinase: basis for differential signaling by CD4 and CD8 in immature thymocytes expressing both coreceptor molecules. J Exp Med 1993; 178:1701-1712.